Drug
Osilodrostat
Osilodrostat: highest development phase Post-Market, developed by Recordati. 4 trial records tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Recordati
Trials
| Drug | Phase | Indication |
|---|---|---|
| Osilodrostat NCT07247162 | Post-Market | Hypertension |
| Osilodrostat (Isturisa) NCT07247058 | Post-Market | Mild Autonomous Cortisol Secretion (MACS) |
| osilodrostat NCT03606408 | Phase 2 | Cushing's Syndrome |
| Osilodrostat 1 MG NCT07104812 | Phase 2 | Mild Autonomous Cortisol Secretion |
Latest
No recent events.
Follow Osilodrostat on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.